CAR T Cell Therapy News
More than 50 years after its discovery, CEA remains one of the most widely used clinical markers of cancer. As the diverse roles of CEA and its family members, known as CEA-related cell adhesion molecules (CEACAMs), have grown clearer, researchers at City of Hope are working on a new wave of clinical tools and therapies.
Sunday, February 4, is World Cancer Day. Here, we’ve spotlighted how teams at City of Hope are improving the care and treatment of patients diagnosed with cancer everywhere.
Christine Brown, Ph.D., co-leads the T Cell Therapeutics Research Laboratory, along with Stephen J. Forman, M.D., which to date has treated more than 100 patients in seven clinical trials, with aggressive goals of opening four new clinical studies within the year.
Xiuli Wang, Ph.D., is at the forefront of one of the most exciting breakthroughs in cancer treatment, chimeric antigen receptor (CAR) T cell therapy.
New blood cancer breakthroughs – including several involving CAR T cell therapy – were announced by City of Hope physicians at the American Society of Hematology (ASH) annual meeting in Atlanta.
Driven in part by the plight of his patients and his father, chief of neurosurgery Behnam Badie, M.D., spends nearly as much time in the laboratory as he does in the operating room. He wants to help not just today's patients, but tomorrow's.
City of Hope announced today that it will present data on an abstract titled “Remissions of Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm Following Treatment with CD123-Specific CAR T Cells: A First-in-Human Clinical Trial” at the American Society of Hematology Annual Meeting Dec. 9 to 12, 2017, at the Georgia World Congress Center in Atlanta.
Say the words “brain tumor” and most people will likely think of cancer. But there’s reason for optimism - recent advances in screening and treatment, such as CAR T cell therapy, mean patient outcomes and quality of life are continuing to improve.
City of Hope will be the one of the first authorized centers in the nation to provide axicabtagene ciloleucel, which the U.S. Food and Drug Administration (FDA) announced today is the first approved CAR T therapy for adult patients who have not responded to or who have relapsed after at least two other kinds of treatment.
A research team led by Christine Brown, Ph.D., and a clinical team headed by Behnam Badie, M.D., chief of neurosurgery, has received a $12.8 million grant from the California Institute for Regenerative Medicine (CIRM) to fund a phase 1 chimeric antigen receptor (CAR) T cell trial targeting an aggressive brain cancer called malignant glioma, which includes glioblastoma. The trial will be open to adults and children.
City of Hope researchers have found that using CAR T therapy, a type of immunotherapy, can be effective in the treatment of glioblastoma — one of the most aggressive brain tumors known to medicine.
T cells were genetically modified in a lab by City of Hope researchers and trained to target specific receptors on patients’ brain tumors - part of an emerging approach to cancer care called immunotherapy.
Studies presented by City of Hope physicians and researchers at the annual meeting of the American Association for Cancer Research (AACR) , could influence future approaches to drug-resistant cancers, treating aggressive brain cancers, recruiting diverse populations for research, and targeted therapies, among other advances.
Dual-trained pediatric oncologist and scientist Leo Wang, M.D., Ph.D., is working in the lab to understand how blood cells develop and grow, and plans to use that information to help patients with cancer live longer and experience fewer side effects of treatment.